Related Experiment Videos

Evidence for a novel function of the CD40 ligand as a signalling molecule in T-lymphocytes

B Brenner1, U Koppenhoefer, H Grassmé

  • 1Department of Physiology, University of Tübingen, Germany.

FEBS Letters
|December 31, 1997
PubMed

Insights

The CD40 ligand (gp39/CD40L) activates T-lymphocytes by stimulating Jun-N-terminal kinase (JNK) and p38 kinases. This pathway involves p56(lck) and Rac1, crucial for T-cell activation.

Area of Science:

  • Immunology
  • Cell Signaling

Background:

  • CD40 receptor-ligand interaction is vital for B-lymphocyte activation.
  • The role of gp39/CD40L in T-lymphocyte activation requires further elucidation.

Purpose of the Study:

  • To investigate the function of gp39/CD40L as a stimulatory molecule for T-lymphocytes.
  • To identify the signaling pathways involved in gp39/CD40L-mediated T-lymphocyte activation.

Main Methods:

  • T-lymphocyte activation assays using gp39/CD40L.
  • Western blotting to detect kinase activation (JNK, p38-K, p56(lck)).
  • Rac1 activity assays and inhibition studies.
  • Analysis of protein tyrosine phosphorylation.

Main Results:

  • gp39/CD40L robustly activates T-lymphocytes, inducing JNK and p38-K activation.
  • Rac1 activation correlates with JNK/p38-K stimulation; Rac1 inhibition blocks this activation.
  • CD40 ligand stimulation leads to protein tyrosine phosphorylation and p56(lck) activation.
  • Inhibition of src-like kinases impairs Rac1 and JNK/p38-K activation.

Conclusions:

  • gp39/CD40L acts as a potent stimulatory molecule for T-lymphocytes.
  • A signaling cascade involving p56(lck) and Rac1 mediates gp39/CD40L-induced JNK/p38-K activation in T-cells.

Related Concept Videos